12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Sat, 11 Jul 2026 17:22:21 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Set-Cookie: UpalLiveSession=eyJpdiI6IkVTbFZuQlJOcUpHNDJuUUZWaTFCb1E9PSIsInZhbHVlIjoicDlMTGMyYmFCU2VZWThTeSs5OEU4cWNVdXdFVUFsYkRiXC9JZWswTjJEMURcL29jazVVVFhkMzRIVjdGeUtBS01qNlY0aFRDUkRxMjlHZnBvbFhGNm96UT09IiwibWFjIjoiNDcyZDQ2NmFkZjg2YTQ4MDA2MDdhZDQyNGQ3YzRmNWIwMTA4MTMxYTNiZDVkMTA3NmNjMTI5NjllMmI5MDJiYiJ9; expires=Tue, 10-Jul-2029 17:22:21 GMT; Max-Age=94608000; path=/; HttpOnly [7] => X-Frame-Options: SAMEORIGIN [8] => X-Content-Type-Options: nosniff [9] => X-Xss-Protection: 1; mode=block [10] => Referrer-Policy: strict-origin-when-cross-origin [11] => Permissions-Policy: geolocation=(), microphone=(), camera=() [12] => Content-Security-Policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => X-Robots-Tag: noindex, nofollow, nosnippet, noarchive [15] => Strict-Transport-Security: max-age=31536000; includeSubDomains; preload [16] => Expires: Sun, 12 Jul 2026 17:22:21 GMT [17] => Vary: Accept-Encoding [18] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [19] => Cf-Cache-Status: DYNAMIC [20] => Speculation-Rules: "/cdn-cgi/speculation" [21] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [22] => Server-Timing: cfEdge;dur=12,cfOrigin;dur=151 [23] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=zy5oyeQRiCOc5DStu%2FBh1ZZUN74QCv8yLJlp9IObPDysjDbc1nPjR7KNs74RF1s2rxOpgKjIHmsRuTECu9S4hpcKEVeHCvKnF3FUv5jUVChDZkypGho6yY6BzH3Sl9a0MKk%3D"}]} [24] => CF-RAY: a1997d61af3af309-SIN [25] => alt-svc: h3=":443"; ma=86400 ) 789

由中国广东省内专家研制、针对新冠肺炎的中成药“肺炎一号”，于周四正式委托药厂量产，药厂预料下周可以陆续出货，供应予省内各医院使用。但该款新药属于医院制剂，根据规定，它只能在已申报的医院内部使用，一般市民暂时无法购买。

据当地媒体报道，该款新药由5味药材制成，配方并未公开，在周二已获得省药品监督管理局优先审批通过，由广东一方制药有限公司生产。按目前公布的资料，该药有效期为半年，仅对轻症患者有治疗功效，并无预防作用，非确诊者毋须服用。，

省药品监管局早前曾进行临床试验，供广州市第八人民医院的50名轻症患者临床服用该款新药，结果50%患者的咳嗽症状消失、52.4%的咽痛症状消失、69.6%的乏力症状消失，整体症状明显好转，具较好的临床价值。

---

// // // //